Search
for
Sort by
Research 30 of 201
- The senescence-like activity of BMS-470539 is associated with anti-fibrotic actions in models of dermal fibrosis
- Can we teach old drugs new tricks?—Repurposing of neuropharmacological drugs for inflammatory skin diseases
- A Window into Mammalian Basement Membrane Development: Insights from the<i>mTurq2-Col4a1</i>Mouse Model
- 014 Tyrosine Kinase 2 Inhibition Ameliorates the Phenotype of Lesional Alopecia Areata Scalp Skin Ex Vivo, and Reverses the Induction of Human Alopecia Areata in a Humanized Mouse Model
- 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
- 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
- 700 Tyrosine kinase 2 inhibition rescues hair follicles from IL-12–mediated immune privilege collapse and reverses the induction of human alopecia areata in a humanized mouse model
- 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
- Linking allergy to mercury to HLA and burning mouth syndrome
- Mapping the molecular and structural specialization of the skin basement membrane for inter-tissue interactions
- Menopause, skin and common dermatoses. Part 4: oral disorders
- Mapping the molecular and structural specialization of the skin basement membrane for inter-tissue interactions
- PROTACs in 2025: from the laboratory concept to clinical breakthrough
- Alopecia androgênica como agravo da infecção por SARS-CoV-2
- FRI0157 OBSERVATIONAL STUDY OF HAIR FALL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH LOW DOSE METHOTREXATE COMPARED TO HEALTHY CONTROLS
- Treating Psoriasis: What Is New About Fumaric Acid Esters?
- THU0189 Safety of four treatment regimens in early rheumatoid arthritis
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Recent Progress in Prostaglandin F<sub>2</sub><i><sub>α</sub></i>Ethanolamide (Prostamide F<sub>2</sub><i><sub>α</sub></i>) Research and Therapeutics
- Potassium channel openers: therapeutic potential in cardiology and medicine
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Novel therapies for alopecia areata: The era of rational drug development
- 916 Gynecologic and hormonal comorbidities of scarring alopecia: A retrospective review
- Modulating the stem cell niche for tissue regeneration
- Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
- The effect of metformin on hirsutism in polycystic ovary syndrome
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study